Literature DB >> 26558226

Ranibizumab alone or in combination with photodynamic therapy vs photodynamic therapy for polypoidal choroidal vasculopathy: a systematic review and Meta-analysis.

Kai Tang1, Jun-Kang Si1, Da-Dong Guo2, Yan Cui2, Yu-Xiang Du1, Xue-Mei Pan3, Hong-Sheng Bi4.   

Abstract

AIM: To compare the efficacy of intravitreal ranibizumab (IVR) alone or in combination with photodynamic therapy (PDT) vs PDT in patients with symptomatic polypoidal choroidal vasculopathy (PCV).
METHODS: A systematic search of a wide range of databases (including PubMed, EMBASE, Cochrane Library and Web of Science) was searched to identify relevant studies. Both randomized controlled trials (RCTs) and non-RCT studies were included. Methodological quality of included literatures was evaluated according to the Newcastle-Ottawa Scale. RevMan 5.2.7 software was used to do the Meta-analysis.
RESULTS: Three RCTs and 6 retrospective studies were included. The results showed that PDT monotherapy had a significantly higher proportion in patients who achieved complete regression of polyps than IVR monotherapy at months 3, 6, and 12 (All P≤0.01), respectively. However, IVR had a tendency to be more effective in improving vision on the basis of RCTs. The proportion of patients who gained complete regression of polyps revealed that there was no significant difference between the combination treatment and PDT monotherapy. The mean change of best-corrected visual acuity (BCVA) from baseline showed that the combination treatment had significant superiority in improving vision vs PDT monotherapy at months 3, 6 and 24 (All P<0.05), respectively. In the mean time, this comparison result was also significant at month 12 (P<0.01) after removal of a heterogeneous study.
CONCLUSION: IVR has non-inferiority compare with PDT either in stabilizing or in improving vision, although it can hardly promote the regression of polyps. The combination treatment of PDT and IVR can exert a synergistic effect on regressing polyps and on maintaining or improving visual acuity. Thus, it can be the first-line therapy for PCV.

Entities:  

Keywords:  Meta-analysis; combination treatment; monotherapy; photodynamic therapy; polypoidal choroidal vasculopathy; ranibizumab; systematic review

Year:  2015        PMID: 26558226      PMCID: PMC4630984          DOI: 10.3980/j.issn.2222-3959.2015.05.36

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  48 in total

1.  Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Yumiko Kurashige; Atsushi Otani; Manabu Sasahara; Yuko Yodoi; Hiroshi Tamura; Akitaka Tsujikawa; Nagahisa Yoshimura
Journal:  Am J Ophthalmol       Date:  2008-07-09       Impact factor: 5.258

2.  Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Ichiro Maruko; Tomohiro Iida; Yukinori Sugano; Masaaki Saito; Tetsuju Sekiryu
Journal:  Am J Ophthalmol       Date:  2011-02-04       Impact factor: 5.258

3.  [Re-treatment guideline of ranibizumab (genetical recombination) in the maintenance phase].

Authors:  Yasuo Tano; Masahito Ohji; Tatsuro Ishibashi; Fumio Shiraga; Takashi Tokoro; Mitsuko Yuzawa; Nagahisa Yoshimura
Journal:  Nippon Ganka Gakkai Zasshi       Date:  2009-11

4.  EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy.

Authors:  Adrian Koh; Won Ki Lee; Lee-Jen Chen; Shih-Jen Chen; Yehia Hashad; Hakyoung Kim; Timothy Y Lai; Stefan Pilz; Paisan Ruamviboonsuk; Erika Tokaji; Annemarie Weisberger; Tock H Lim
Journal:  Retina       Date:  2012-09       Impact factor: 4.256

5.  Combination of ranibizumab with photodynamic therapy vs ranibizumab monotherapy in the treatment of age-related macular degeneration: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Jun-Kang Si; Kai Tang; Hong-Sheng Bi; Da-Dong Guo; Jun-Guo Guo; Yu-Xiang Du; Yan Cui; Xue-Mei Pan; Ying Wen; Xing-Rong Wang
Journal:  Int J Ophthalmol       Date:  2014-06-18       Impact factor: 1.779

6.  Photodynamic therapy with or without intravitreal triamcinolone acetonide for symptomatic polypoidal choroidal vasculopathy.

Authors:  Timothy Y Y Lai; Carol P S Lam; Fiona O J Luk; Rose P S Chan; Wai-Man Chan; David T L Liu; Dennis S C Lam
Journal:  J Ocul Pharmacol Ther       Date:  2010-02       Impact factor: 2.671

7.  Intravitreal ranibizumab for polypoidal choroidal vasculopathy with recurrent or residual exudation.

Authors:  Masaaki Saito; Tomohiro Iida; Mariko Kano
Journal:  Retina       Date:  2011-09       Impact factor: 4.256

8.  Role of photodynamic therapy in polypoidal choroidal vasculopathy.

Authors:  Eriko Akaza; Mitsuko Yuzawa; Yoko Matsumoto; Shiho Kashiwakura; Kyoko Fujita; Ryusaburo Mori
Journal:  Jpn J Ophthalmol       Date:  2007-08-03       Impact factor: 2.447

9.  Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy.

Authors:  Eriko Akaza; Ryusaburo Mori; Mitsuko Yuzawa
Journal:  Retina       Date:  2008-05       Impact factor: 4.256

10.  Photodynamic therapy versus combination therapy in polypoidal choroidal vasculopathy: changes of aqueous vascular endothelial growth factor.

Authors:  Mee Yon Lee; Won Ki Lee; Jiwon Baek; Oh Woong Kwon; Jin Hae Lee
Journal:  Am J Ophthalmol       Date:  2013-05-09       Impact factor: 5.258

View more
  10 in total

1.  Combined therapy versus anti-vascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy: a Meta-analysis.

Authors:  Long-Hui Han; Li-Fei Yuan; Xu Liang; Xin Jia; Ming-Lian Zhang
Journal:  Int J Ophthalmol       Date:  2017-08-18       Impact factor: 1.779

2.  One-year real-world outcomes of ranibizumab 0.5 mg treatment in Taiwanese patients with polypoidal choroidal vasculopathy: a subgroup analysis of the REAL study.

Authors:  San-Ni Chen; Cheng-Kuo Cheng; Ling Yeung; Jiann-Torng Chen; Wei-Chun Chan; Jorn-Hon Liu; Shwu-Jiuan Sheu; Wen-Chuan Wu; Chi-Chun Lai
Journal:  Int J Ophthalmol       Date:  2018-11-18       Impact factor: 1.779

3.  Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.

Authors:  Adrian Koh; Timothy Y Y Lai; Kanji Takahashi; Tien Y Wong; Lee-Jen Chen; Paisan Ruamviboonsuk; Colin S Tan; Chrystel Feller; Philippe Margaron; Tock H Lim; Won Ki Lee
Journal:  JAMA Ophthalmol       Date:  2017-11-01       Impact factor: 7.389

4.  Treatment of experimental autoimmune uveoretinitis with different natural compounds.

Authors:  Man Li; Xiaoming Chen; Juanjuan Liu; Dongmei Wang; Lu Gan; Xin Lv; Yu Qiao
Journal:  Mol Med Rep       Date:  2016-04-08       Impact factor: 2.952

Review 5.  Polypoidal choroidal vasculopathy: An update on current management and review of literature.

Authors:  Amit Harishchandra Palkar; Vikas Khetan
Journal:  Taiwan J Ophthalmol       Date:  2019 Apr-Jun

6.  Systematic review with network meta-analysis of antivascular endothelial growth factor use in managing polypoidal choroidal vasculopathy.

Authors:  Sheng-Chu Chi; Yi-No Kang; Yi-Ming Huang
Journal:  Sci Rep       Date:  2021-02-02       Impact factor: 4.379

7.  Real world experience of the treatment outcome between photodynamic therapy combined with ranibizumab and aflibercept monotherapy in polypoidal choroidal vasculopathy.

Authors:  I-Hsin Ma; Yun Hsia; Yi-Ting Hsieh; Tzyy-Chang Ho; Tso-Ting Lai; Chung-May Yang; Chang-Hao Yang
Journal:  Sci Rep       Date:  2021-10-11       Impact factor: 4.379

8.  23-Gauge vitrectomy with external drainage therapy as a novel procedure to displace massive submacular hemorrhage secondary to polypoidal choroidal vasculopathy.

Authors:  Hui Liu; Lu-Yi Zhang; Xiao-Xia Li; Miao-Qin Wu
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

Review 9.  Polypoidal choroidal vasculopathy treatment options: A meta-analysis.

Authors:  Tianwei Qian; Xinxin Li; Mengya Zhao; Xun Xu
Journal:  Eur J Clin Invest       Date:  2017-12-18       Impact factor: 4.686

10.  Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial.

Authors:  Tock H Lim; Timothy Y Y Lai; Kanji Takahashi; Tien Y Wong; Lee-Jen Chen; Paisan Ruamviboonsuk; Colin S Tan; Won Ki Lee; Chui Ming Gemmy Cheung; Nor Fariza Ngah; Ramune Patalauskaite; Philippe Margaron; Adrian Koh
Journal:  JAMA Ophthalmol       Date:  2020-09-01       Impact factor: 7.389

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.